A shadow economy for unlicensed slimming medications is being driven by social media fitness personalities and vendors on communication apps, based on new investigations.
Experimental Drug Gaining Popularity Via Social Media
Retatrutide, which is still in clinical trials, is being promoted by social media influencers for its alleged weight-reducing properties. Viewers are urged to message these profiles directly for source information, while also receiving promotional offers.
Active Commerce on Messaging Platforms
Separately, a robust market exists on Telegram, where communities with numerous of participants share “before and after” images, injection guides and assertions of rapid British shipping. Vendors market the drug there before directing customers to WhatsApp for purchases.
Learning About Retatrutide
This medication is an experimental injection created by US drugmaker Eli Lilly. The treatment affects three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies suggest it could assist patients lose up to a quarter of their total weight. Nicknamed the “triple G”, the drug is being promoted online as the successor to Ozempic.
Medical Experts Express Concerns
Nevertheless, doctors and pharmacists have cautions that the distribution of what is still an unapproved medication in the United Kingdom is worrisome and could result in individuals injecting substances of unknown origin.
Some professionals stated the demand for retatrutide could be linked to the rising cost of approved weight loss treatments such as Mounjaro.
Regulatory Position and Implementation
Selling the unapproved drug on social media or Telegram is illegal in the United Kingdom, as it is an unlicensed medication that cannot be marketed or distributed for personal consumption under the British medical regulations.
Some influencers try to sidestep the regulations by referring to the substance as a “research chemical” or describing it as “not for human consumption”. The substance is not a restricted substance, but promotion and supply can still violate pharmaceutical, advertising, and consumer laws, potentially leading to penalties, legal action or imprisonment.
Service Response and Content Removal
Based on the social media company, the service has taken down problematic content and prohibited associated keywords and query recommendations. The organization stated it was dedicated to maintaining the platform safe and investing in enhancing compliance measures.
Digital Marketplace Operations
Research also discovered communities with up to nine thousand participants selling the experimental drug using the platform's integrated search feature, which operates like a public directory. Typing “retatrutide” immediately brings up channels with numerous of members, filled with images of weight loss, glowing reviews and step-by-step guides for preparing or injecting at home.
Within minutes of entering one group, a seller posted contact information, where the majority of purchases take place. The seller provided an instruction manual and promised delivery within 48 hours. When questioned whether the product was genuine, one vendor responded: “You can’t be sure.” Another shared a image of a supposed laboratory certificate. Not one asked about weight, medical conditions or previous experience.
Item Details and Costs
Inside these groups, posts show black plastic packages with postal service labels, claiming to contain fresh supplies. One message read: “It took eight of us to load them this morning.”
Customers can select between powder vials, mixed at home with purified liquid, or ready-to-use pens usually sold at 160 pounds for 20mg. When questioned how much time a pen should last, sellers give conflicting answers varying between a few weeks to “depends on your body”.
Platform Moderation and Safety Measures
A representative for the messaging service said it actively moderated dangerous content on its service including material that encouraged the “misuse of controlled medications”. The organization noted that it removed “millions of pieces of harmful content each day”.
Healthcare Expert Warnings
“People are administering substances they cannot confirm. Although the research behind this drug is valid, these digital products may not contain what they advertise,” said Jason Murphy, the head of pharmaceutical services at Chemist4U.
A medical professional of Asda Online Doctor connected the surge in interest to recent price rises for authorized weight-loss medications such as Mounjaro. “With costs increasing, patients are turning to social media. But fake treatments are highly dangerous. You cannot know what’s inside or whether the environment they were produced in was sterile,” she said.
Her staff has already seen patients injured by self-injection from unconfirmed suppliers. “We recognize the disappointment, but buying from messaging apps or communication platforms is taking chances with your well-being,” stated Wyllie. “These substances could be contaminated or improperly measured.”
Producer Position
A spokesperson from the pharmaceutical company said retatrutide was in phase 3 clinical trials and had not been reviewed or authorized by any regulatory agency globally. “Therefore at this point no one can sell [it] for personal consumption,” they explained, adding that any item “misleadingly claiming itself as a Lilly experimental substance not yet authorized … may expose users to potentially serious medical dangers”.
